Idiomas Sample Clauses

Idiomas. El presente Contrato se celebra en inglés y español, sin embargo, la versión en español prevalecerá.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Idiomas. Las partes firman y celebran el presente contrato en los idiomas Español e Ingles; en caso de discrepancia entre las dos versiones, la versión en Español prevalecerá. Las partes reconocen xxxxx obtenido el suficiente asesoramiento legal independiente y el xxxxx leído y entendido (a través de sus respectivos intérpretes y asesores legales) los efectos legales y validez del presente Contrato en las versiones Español e Ingles. La versión en Ingles se anexa para referencia como anexo C, el cual forma parte íntegra del mismo para todos los efectos legales a que xxxx xxxxx. EN XXXXXXXXXX XX XX ANTERIOR las partes celebran el presente Contrato en la fecha antes señalada. “CEDENTE” MINERA RIO TINTO, S. A. DE C. V. _______________________________________ XXXXX XXXX TOUCHE ADMINISTRADOR UNICO “CESIONARIA” SUNBURST MINING DE MEXICO, S. A. DE C. V. _______________________________________ XXXXX XXXXX XXXXX ADMINISTRADOR UNICO “CONCESIONARIO” _______________________________________ XXXXXX XXXXXXXX XXXXXXX XXXXXXXXX POR SUS PROPIOS DERECHOS ANEXO A XXXXXXXX XX XXXXXX XXX XXXXXXX XXXXX X REGALIAS SOBRE LIQUIDACIONES NETAS DE FUNDICION ARTICULO I DEFINICIONES Todos los términos en mayúsculas que se utilicen pero que no xxxx definidos en el presente Anexo deberán tener el significado asignados a dichos términos en el presente Contrato. Los términos siguientes los cuales son utilizados en el presente instrumento deberán tener los siguientes significados (en caso que cualquier término o definición en este Anexo estuviera en conflicto con algún término o definición señalado en el Contrato, el término o definición en el presente Anexo xxxxxx prevalecer o gobernar):
Sample 1
Idiomas. Xx xxxx de qualquer conflito entre a versão xx xxxxxx e a versão em português deste Contrato, a versão xx xxxxxx prevalecerá.
Sample 1
Idiomas. 9.2. El presente MdE se firma por duplicado en español e inglés, teniendo ambas versiones el mismo valor jurídico. Xx xxxxxxxx xx xxxxx partes que todas las versiones xxxx iguales en contenido, xxxxxxxx e interpretación. Firmado en nombre y representación de la Universidad de Las Palmas de Gran Canaria Firma y sello: Q3518001G) 46114240E Firmado digitalmente por 46114240E XXXX Nombre: Xxxx Xxxxx Xxxxx XXXX XXXXX (R: XXXXX (R: Fecha: Q3518001G) Fecha: 2023.11.27 16:16:35 Z Firmado en nombre y representación de CENTIMFE - Centro Tecnológico da Indústria de Moldes, Ferramentas Especiais e Plásticos Firma y sello: Assinado por: Xxxx Xxxxxx xx Xxxxx Xxxxxxx xx Xxxxx Num. de Identificação: 09461344 Assinado por: Xxxxx Xxxxxx Xxxxxxx Xxxxxxx Xxxxxxxx Num. de Identificação: 08765682 Data: 2024.01.23 17:31:46+00'00' Nombre: Nuno SDialtva:a20a24n.0d1.2J4 o09r:2g3e:39F+e00r0r0eira
Sample 1
Idiomas. En caso de conflicto entre la versión en Inglés y la versión en Español de este Contrato, la versión en Inglés prevalecerá.
Sample 1

Related to Idiomas

  • XXXREAS the Trust is registered under the Investment Company Act of 1940, as amended, (the "1940 Act") as an open-end, series management investment company; and

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Royalty Floor Notwithstanding the foregoing, during any Calendar Quarter in the Royalty Term for a Licensed Product in a particular region in the Territory, the operation of Section 9.3(c), individually or in combination shall not reduce the final royalty rate to [***].

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Field The term “

  • XXXXXAS xx xxcordance xxxx Xxxx 00x-1(k) xxder the Securities Exchange Act of 1934 (the "Act"), only one statement containing the information required by Schedule 13G and any amendments thereto need be filed whenever two or more persons are required to file such a statement or any amendments thereto with respect to the same securities, provided that said persons agree in writing that such statement or any amendment thereto is filed on behalf of them.

Time is Money Join Law Insider Premium to draft better contracts faster.